<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290744</url>
  </required_header>
  <id_info>
    <org_study_id>LWM-2010-ENL</org_study_id>
    <nct_id>NCT01290744</nct_id>
  </id_info>
  <brief_title>Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy</brief_title>
  <official_title>Effect of Additional Clofazimine on ENL Reactions in Leprosy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paul Saunderson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leonard Wood Memorial</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, randomized controlled trial examining the effect on ENL
      reactions of giving an additional year of clofazimine after completion of MDT in leprosy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clofazimine is an anti-bacterial agent used to treat leprosy; it is a normal component of
      WHO-recommended multi-drug therapy (MDT). It is also known to have a beneficial effect in one
      of the common immunological reactions that occur in leprosy, known as erythema nodosum
      leprosum, or ENL. When MDT was reduced in length from 24 to 12 months, evidence suggests that
      ENL became worse. This study is a double-blind, randomized controlled trial examining the
      effect of giving an additional year of clofazimine after completion of MDT. The endpoints are
      the incidence and severity of ENL over a period of 3 years in the 2 groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ENL reactions</measure>
    <time_frame>2 years of follow-up</time_frame>
    <description>The hypothesis is that additional clofazimine will reduce the incidence of ENL reactions in the two years following completion of MDT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of ENL reactions</measure>
    <time_frame>2 years of follow-up</time_frame>
    <description>The hypothesis is that additional clofazimine will reduce severity of ENL reactions, as well as incidence. Severity will be monitored by three indicators: 1. a rather crude clinical score (mild, moderate or severe), 2. the total dose of prednisolone given to treat ENL reactions, 3. the total duration of ENL symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Borderline Lepromatous Leprosy</condition>
  <condition>Lepromatous Leprosy</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>These patients will receive placebo for 12 months after completion of MDT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clofazimine for 12 months after MDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given clofazimine (100mg daily) for 12 months after completion of MDT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
    <description>Clofazimine 100mg daily for 12 months after completion of MDT.</description>
    <arm_group_label>Clofazimine for 12 months after MDT</arm_group_label>
    <other_name>Lamprene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily for 12 months</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Vitamin capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  15 to 70 years of age

          -  MB leprosy

          -  Pretreatment BI of 4 or more at any site

          -  Consent

        Exclusion Criteria:

          -  Presence of another serious illness

          -  Refusal of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marivic Balagon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LWM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cebu Skin Clinic</name>
      <address>
        <city>Cebu</city>
        <state>Vesayas</state>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Leonard Wood Memorial</investigator_affiliation>
    <investigator_full_name>Paul Saunderson</investigator_full_name>
    <investigator_title>Scientific Director</investigator_title>
  </responsible_party>
  <keyword>leprosy</keyword>
  <keyword>ENL</keyword>
  <keyword>clofazimine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leprosy</mesh_term>
    <mesh_term>Leprosy, Lepromatous</mesh_term>
    <mesh_term>Leprosy, Multibacillary</mesh_term>
    <mesh_term>Leprosy, Borderline</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

